SecBot SecBot

VRDN

Viridian Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001590750 Biotech & Drug Discovery
$22.89 +0.52 (+2.32%)
Oct 26 4:00 PM ET · prev $22.37
Market cap
$2.6B
Mid cap
Consensus
Buy
96% Buy or better · 23 analysts
Median target
🔒 Subscribers only
Next earnings
Nov 4
in 9 days · EPS est. −$1.02
1 year
+1.6%
from $22.54 · Oct 27
30 days
+11.3%
from $20.57
52-week range
$13.30–33.78
−32% from high · low Apr 29
Avg volume 20D
1.98M
shares / day
Short interest
17.97M
≈15.9% of shares · −7.7%
Days to cover
8.9
at average volume
Insider net
+$19.7M
1 buyer · 1 seller · 12 mo
New fund stakes
1
Q2 2026 13F · 2 exits
SecBot read BULLISH 1 report · 90 days
Balance 0 bearish · 1 bullish oldest → newest, height = score
Avg score ·High conf. 1/1 ·Next Earnings date, Nov 4, 2026
Strongest BULLISH Viridian Therapeutics reported Q2 2026 results highlighting the FDA approval and U.S. launch of Lumvoa…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $20.0M at an average $17.00. 1 insider sold $348.2K. Price is 35% above their cost.

  • InstitutionsMIXED

    Q2 2026: 31 added (1 new), 25 trimmed or exited. Largest new: Schonfeld Strategic Advisors $14.6M.

  • AnalystsBULLISH

    22 of 23 rate it Buy or better.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.928 → −$1.025 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest −7.7% to 17.97M shares. 8.9 days to cover, ≈15.9% of shares.

  • TrendRANGE

    6% above its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
2
exits
$14.6M
in new stakes
FundMoveSharesValue
STATE STREET CORPADD6,124,976$112.5M
PRICE T ROWE ASSOCIATES INC /MD/ADD5,748,410$105.6M
VANGUARD PORTFOLIO MANAGEMENT LLCADD2,752,827$50.6M
Avoro Capital Advisors LLCADD2,500,000$45.9M
Point72 Asset Management, L.P.DOUBLED2,343,208$43.0M
Candriam S.C.A.DOUBLED1,707,698$31.3M
DIMENSIONAL FUND ADVISORS LPDOUBLED1,611,521$29.6M
UBS Group AGDOUBLED1,428,843$26.2M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

23 analysts
Buy 96% rate it Buy or better
Strong Buy8Buy14Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Sep 22, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Aug 7, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Aug 7, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Jun 30, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Jun 30, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Jun 30, 2026Wedbush
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$20.0M
bought · 1 insider
$348.2K
sold · 1 insider
+34.6%
vs their $17.00 cost
DateInsiderTypeValue
Aug 19, 2026
Tousignant Jennifer
Chief Legal Officer
SELL$103.2K
Aug 19, 2026
Tousignant Jennifer
Chief Legal Officer
EXERCISE$144.1K
Aug 19, 2026
Tousignant Jennifer
Chief Legal Officer
SELL$245.0K
Aug 14, 2026
Tripuraneni Radhika
Chief Medical Officer
EXERCISE$528.4K
Jul 1, 2026
Kiselak Tomas
Director
AWARD32,341 sh
Jul 1, 2026
Gheuens Sarah
Director
AWARD32,341 sh
Jul 1, 2026
Moses Jennifer K.
Director
AWARD32,341 sh
Jul 1, 2026
CAIN CHRISTOPHER W.
Director
AWARD32,341 sh

Earnings setup

Estimates
Nov 4
reports in 9 days
−$1.02
EPS estimate, this quarter
−10%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.02-$1.26–-$0.78-3.5%$4.7M
Next Q-$0.95-$1.21–-$0.71+4.6%$19.3M
Current FY-$3.94-$4.60–-$3.41+0.2%$24.4M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
17,965,668
shares short
-7.7%
vs prior settlement
8.9
days to cover
≈15.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 25, 2026 Clinical trial readout
Results Pending: VRDN-003 (Phase 3) — Completed 89d ago
Trial: A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Ey
Aug 19, 2026 Insider
Tousignant Jennifer sold 4,212 shares
Chief Legal Officer @ $24.50 ($103.2K)
Aug 19, 2026 Insider
Tousignant Jennifer acquired via exercise 10,000 shares
Chief Legal Officer @ $14.41 ($144.1K)
Aug 19, 2026 Insider
Tousignant Jennifer sold 10,000 shares
Chief Legal Officer @ $24.50 ($245.0K)
Aug 6, 2026 SEC
Viridian Therapeutics reported Q2 2026 results highlighting the FDA approval and U.S. launch of Lumvoa…
8-K — Impact 7/10
Jun 30, 2026 Inst.
STATE STREET CORP — ADD
6,124,976 shares ($112.5M)
Jun 30, 2026 Inst.
PRICE T ROWE ASSOCIATES — ADD
5,748,410 shares ($105.6M)
Jun 26, 2026 Event
LUMVOA
Original Approval — Type 1 - New Molecular Entity — INJECTION
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 4, 2026
Earnings date
VRDN Q3 2026 Earnings Scheduled — 2026-11-04
Recent
Aug 25, 2026
Trial readout
Results Pending: VRDN-003 (Phase 3) — Completed 89d ago
Trial: A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED) Sponsor: Viridian Therapeutics…
Aug 14, 2026
Clinical Trial
An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301
Phase 3 · COMPLETED
Aug 13, 2026
Clinical Trial
A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)
Phase 3 · COMPLETED
Aug 13, 2026
Clinical Trial
A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)
Phase 3 · COMPLETED
Aug 13, 2026
Clinical Trial
An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)
Phase 3 · COMPLETED

SecBot reports

8 filings · 2 bullish · 1 bearish · 2 mixed · 3 neutral
All VRDN filing & press-release reports (8)